JP2020147591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020147591A5 JP2020147591A5 JP2020100620A JP2020100620A JP2020147591A5 JP 2020147591 A5 JP2020147591 A5 JP 2020147591A5 JP 2020100620 A JP2020100620 A JP 2020100620A JP 2020100620 A JP2020100620 A JP 2020100620A JP 2020147591 A5 JP2020147591 A5 JP 2020147591A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- composition
- fragment
- composition according
- tolerance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022147649A JP2022184955A (ja) | 2012-02-15 | 2022-09-16 | 赤血球結合治療剤 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/397,202 US9517257B2 (en) | 2010-08-10 | 2012-02-15 | Erythrocyte-binding therapeutics |
| US13/397,202 | 2012-02-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018039593A Division JP6716619B2 (ja) | 2012-02-15 | 2018-03-06 | 赤血球結合治療剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022147649A Division JP2022184955A (ja) | 2012-02-15 | 2022-09-16 | 赤血球結合治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020147591A JP2020147591A (ja) | 2020-09-17 |
| JP2020147591A5 true JP2020147591A5 (enExample) | 2020-11-05 |
Family
ID=48326347
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557135A Active JP6692602B2 (ja) | 2012-02-15 | 2013-02-15 | 赤血球結合治療剤 |
| JP2018039593A Active JP6716619B2 (ja) | 2012-02-15 | 2018-03-06 | 赤血球結合治療剤 |
| JP2020100620A Pending JP2020147591A (ja) | 2012-02-15 | 2020-06-10 | 赤血球結合治療剤 |
| JP2022147649A Pending JP2022184955A (ja) | 2012-02-15 | 2022-09-16 | 赤血球結合治療剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557135A Active JP6692602B2 (ja) | 2012-02-15 | 2013-02-15 | 赤血球結合治療剤 |
| JP2018039593A Active JP6716619B2 (ja) | 2012-02-15 | 2018-03-06 | 赤血球結合治療剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022147649A Pending JP2022184955A (ja) | 2012-02-15 | 2022-09-16 | 赤血球結合治療剤 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2814500B1 (enExample) |
| JP (4) | JP6692602B2 (enExample) |
| KR (1) | KR20150010699A (enExample) |
| CN (3) | CN110075284A (enExample) |
| AU (2) | AU2013220079B2 (enExample) |
| BR (1) | BR112014020304A8 (enExample) |
| CA (1) | CA2864432A1 (enExample) |
| EA (2) | EA028087B1 (enExample) |
| ES (1) | ES2781773T3 (enExample) |
| HK (1) | HK1202051A1 (enExample) |
| IL (1) | IL234056B (enExample) |
| MX (1) | MX2014009900A (enExample) |
| NZ (2) | NZ628851A (enExample) |
| SG (2) | SG11201404943PA (enExample) |
| WO (1) | WO2013121296A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2709176T3 (es) | 2006-08-11 | 2019-04-15 | Life Sciences Res Partners Vzw | Péptidos inmunogénicos y su uso en trastornos inmunitarios |
| EP2626081B1 (en) | 2008-02-14 | 2017-03-22 | Life Sciences Research Partners VZW | Immunogenic control of tumours and tumour cells |
| ES2637812T3 (es) | 2008-02-14 | 2017-10-17 | Life Sciences Research Partners Vzw | Inmunoterapia dirigida a patógenos intracelulares |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| EP2603520A4 (en) | 2010-08-10 | 2014-02-19 | Ecole Polytech | ERYTHROCYTE BINDING THERAPEUTICS |
| DE11787873T1 (de) | 2010-11-25 | 2013-12-12 | Imnate Sarl | Immugene Peptide zur Verwendung bei der Vorbeugung und/oder Behandlung von Infektionskrankheiten, Autoimmunerkrankungen, Immunreaktionen auf Allofaktoren, allergischen Erkrankungen, Tumoren, Transplantatabstossungen und Immunreaktionen auf virale Vektoren |
| CA2897505A1 (en) * | 2013-01-18 | 2014-07-24 | Glycotope Gmbh | Peptides for enhancing protein expression |
| GB201309469D0 (en) | 2013-05-28 | 2013-07-10 | Imcyse Sa | Detection of CD4+ T lymphocytes |
| CA2930665A1 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| SG11201606761RA (en) | 2014-02-21 | 2016-09-29 | Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| MA39819A (fr) | 2014-04-01 | 2017-02-08 | Rubius Therapeutics Inc | Méthodes et compositions d'immunomodulation |
| GB201418433D0 (en) | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US10729791B2 (en) * | 2015-05-18 | 2020-08-04 | Imcyse Sa | Animal models for evaluating pharmaceutical compounds |
| KR20180080195A (ko) * | 2015-09-19 | 2018-07-11 | 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) | 글리코타겟팅 치료제 |
| CA2995771A1 (en) | 2015-09-25 | 2017-03-30 | Imcyse Sa | Improved methods and compounds for eliminating immune responses to therapeutic agents |
| EP3365013B1 (en) * | 2015-10-23 | 2020-12-09 | Immix Biopharma, Inc. | Methods and related compositions for the treatment of cancer |
| WO2017124102A1 (en) | 2016-01-14 | 2017-07-20 | North Carolina State University | Glucose responsive insulin delivery compositions and methods |
| BR112018071466A2 (pt) | 2016-04-19 | 2019-03-19 | Imcyse Sa | novos peptídeos de ligação a cd1d imunogênicos |
| CA3023092A1 (en) * | 2016-05-03 | 2017-11-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to induce tolerance |
| CA3025988A1 (en) | 2016-06-02 | 2017-12-07 | Sanofi | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein |
| WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| JP7278270B2 (ja) * | 2017-10-20 | 2023-05-19 | シーエスエル、リミテッド | 方法 |
| CN111433193A (zh) | 2017-12-01 | 2020-07-17 | 赛诺菲 | 药剂和能够结合至葡萄糖传感蛋白的部分的新型缀合物 |
| JP2021522812A (ja) * | 2018-05-07 | 2021-09-02 | アノキオン・ソシエテ・アノニムＡｎｏｋｉｏｎ Ｓａ | グリコフォリンａ抗原結合タンパク質 |
| EP3790577A4 (en) | 2018-05-09 | 2022-04-27 | The University of Chicago | COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE |
| US20220348637A1 (en) | 2019-11-11 | 2022-11-03 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| US20230184766A1 (en) * | 2020-05-01 | 2023-06-15 | The Johns Hopkins University | Compositions and methods for coronavirus detection |
| US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| US20240277768A1 (en) * | 2021-06-17 | 2024-08-22 | Tihamer Orban | Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells |
| EP4384219A4 (en) | 2021-08-10 | 2025-06-18 | Viridian Therapeutics, Inc. | COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE |
| CN116731962B (zh) * | 2023-08-14 | 2023-11-03 | 天津中新科炬生物制药股份有限公司 | 全血中分离红细胞的试剂盒及方法 |
| CN118184737A (zh) * | 2024-04-25 | 2024-06-14 | 北京睿脉医药科技有限公司 | 一种特异性结合红细胞膜的多肽或其突变体 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5227293A (en) | 1989-08-29 | 1993-07-13 | The General Hospital Corporation | Fusion proteins, their preparation and use |
| US5358857A (en) | 1989-08-29 | 1994-10-25 | The General Hospital Corp. | Method of preparing fusion proteins |
| US5227165A (en) | 1989-11-13 | 1993-07-13 | Nova Pharmaceutical Corporation | Liposphere delivery systems for local anesthetics |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
| AU696964B2 (en) * | 1994-02-28 | 1998-09-24 | University Of Virginia Patent Foundation | Antigen-based heteropolymers and method for treating autoimmune diseases using the same |
| US6512103B1 (en) | 1995-12-08 | 2003-01-28 | Schering Corporation | Mammalian chemokine reagents |
| EP0930874A2 (en) | 1996-10-09 | 1999-07-28 | Takeda Chemical Industries, Ltd. | A method for producing a microparticle |
| US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
| US5948639A (en) | 1997-04-10 | 1999-09-07 | Millennium Pharmaceuticals, Inc. | TGF-β pathway genes |
| NZ500284A (en) | 1997-04-18 | 2001-09-28 | Biogen Inc | Type II TGF-beta receptor fusion proteins |
| WO1999046392A1 (en) | 1998-03-12 | 1999-09-16 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines |
| US6224794B1 (en) | 1998-05-06 | 2001-05-01 | Angiotech Pharmaceuticals, Inc. | Methods for microsphere production |
| AU4572899A (en) | 1998-06-16 | 2000-01-05 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| CA2345024C (en) | 1998-10-07 | 2009-05-19 | Stryker Corporation | Modified tgf-.beta. superfamily proteins |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| GB0019302D0 (en) | 2000-08-08 | 2000-09-27 | Univ Nottingham Trent | Biological materials and the use thereof for the treatment of disease |
| US7470420B2 (en) | 2000-12-05 | 2008-12-30 | The Regents Of The University Of California | Optical determination of glucose utilizing boronic acid adducts |
| US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
| CA2471532A1 (en) | 2001-10-23 | 2003-05-01 | Centre For Translational Research In Cancer | A synthetic chimeric fusion protein with immuno-therapeutic uses |
| WO2005051174A2 (en) | 2003-11-21 | 2005-06-09 | The Trustees Of Columbia University In The City Of New York | Nucleic acid aptamer-based compositions and methods |
| US8617819B2 (en) | 2004-09-17 | 2013-12-31 | Massachusetts Institute Of Technology | Polymers for analyte detection |
| US7811809B2 (en) | 2005-06-15 | 2010-10-12 | Saint Louis University | Molecular biosensors for use in competition assays |
| US7892734B2 (en) | 2005-08-11 | 2011-02-22 | The Board Of Trustees Of The University Of Illinois | Aptamer based colorimetric sensor systems |
| US8021689B2 (en) | 2006-02-21 | 2011-09-20 | Ecole Polytechnique Federale de Lausanne (“EPFL”) | Nanoparticles for immunotherapy |
| CN101743249B (zh) | 2007-05-11 | 2017-08-08 | 阿尔托生物科学有限公司 | 融合分子与il‑15变异体 |
| US8852640B2 (en) | 2008-07-03 | 2014-10-07 | Ecole Polytechnique Federale De Lausanne (Epfl) | Micelles for delivery of nitric oxide |
| US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| US8268977B2 (en) | 2008-11-20 | 2012-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Strongly quenching oligomeric excimer/quencher pairs for detection schemes |
| AU2010311515B2 (en) | 2009-10-27 | 2014-02-20 | Erytech Pharma | Composition to induce specific immune tolerance |
| US9517257B2 (en) * | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| EP2603520A4 (en) * | 2010-08-10 | 2014-02-19 | Ecole Polytech | ERYTHROCYTE BINDING THERAPEUTICS |
-
2013
- 2013-02-15 WO PCT/IB2013/000684 patent/WO2013121296A1/en not_active Ceased
- 2013-02-15 AU AU2013220079A patent/AU2013220079B2/en active Active
- 2013-02-15 HK HK15102492.2A patent/HK1202051A1/xx unknown
- 2013-02-15 KR KR20147025631A patent/KR20150010699A/ko not_active Ceased
- 2013-02-15 CA CA2864432A patent/CA2864432A1/en not_active Abandoned
- 2013-02-15 EA EA201491524A patent/EA028087B1/ru unknown
- 2013-02-15 NZ NZ628851A patent/NZ628851A/en unknown
- 2013-02-15 JP JP2014557135A patent/JP6692602B2/ja active Active
- 2013-02-15 MX MX2014009900A patent/MX2014009900A/es unknown
- 2013-02-15 EP EP13721386.4A patent/EP2814500B1/en active Active
- 2013-02-15 ES ES13721386T patent/ES2781773T3/es active Active
- 2013-02-15 BR BR112014020304A patent/BR112014020304A8/pt not_active Application Discontinuation
- 2013-02-15 EA EA201790862A patent/EA035931B1/ru unknown
- 2013-02-15 CN CN201811569743.5A patent/CN110075284A/zh active Pending
- 2013-02-15 SG SG11201404943PA patent/SG11201404943PA/en unknown
- 2013-02-15 SG SG10201609500QA patent/SG10201609500QA/en unknown
- 2013-02-15 CN CN201380019578.5A patent/CN104271148A/zh active Pending
- 2013-02-15 CN CN201811569705.XA patent/CN110075283A/zh active Pending
- 2013-02-15 NZ NZ722352A patent/NZ722352A/en unknown
-
2014
- 2014-08-11 IL IL234056A patent/IL234056B/en active IP Right Grant
-
2017
- 2017-12-13 AU AU2017276218A patent/AU2017276218B2/en active Active
-
2018
- 2018-03-06 JP JP2018039593A patent/JP6716619B2/ja active Active
-
2020
- 2020-06-10 JP JP2020100620A patent/JP2020147591A/ja active Pending
-
2022
- 2022-09-16 JP JP2022147649A patent/JP2022184955A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020147591A5 (enExample) | ||
| JP2018127458A5 (enExample) | ||
| JP2017008046A5 (enExample) | ||
| Rewers et al. | Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future | |
| CN105189562B (zh) | Il-15异源二聚体蛋白及其用途 | |
| JP2004501101A5 (enExample) | ||
| EP0380230A2 (en) | Immunogenic compositions against gastrin peptides | |
| JP2022553826A5 (enExample) | ||
| WO2007147090A3 (en) | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity | |
| JP2009544761A5 (enExample) | ||
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| JP2012500006A5 (enExample) | ||
| JP2024156682A5 (enExample) | ||
| FI4358995T3 (fi) | Mystostatiinireitin estäjä yhdessä glp-1-reitin aktivaattorin kanssa käytettäviksi metabolisten häiriöiden hoidossa | |
| JP2018530574A5 (enExample) | ||
| JP2009519025A5 (enExample) | ||
| JP2019526244A5 (enExample) | ||
| JP2013193995A (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| JP2024515066A5 (enExample) | ||
| WO2024250865A1 (zh) | 嵌合抗原受体及其应用 | |
| JP5646506B2 (ja) | 腸の炎症性疾患及び１型糖尿病を治療するためのａｐｌ型ペプチドの使用 | |
| JP2023545084A5 (enExample) | ||
| IL323508A (en) | Methods and uses for treating nausea and vomiting | |
| Monsonego et al. | Beneficial effect of orally administered myelin basic protein inEAE-susceptible Lewis rats in a model of acute CNSdegeneration | |
| Davies et al. | Efpeglenatide: a once monthly GLP-1 RA in the pipeline |